文献速递肿瘤 PET/CT

FDG-PET/CT用于头颈部鳞状细胞癌治疗反应评估:诊断性能的系统综述与Meta分析

FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2018-02-24

该系统综述与Meta分析纳入20项研究共1293例头颈部鳞状细胞癌患者,评估治疗后6个月内FDG-PET/CT检测淋巴结病变的诊断价值。汇总敏感度85%、特异度93%、诊断比值比76;HPV阳性肿瘤敏感度和特异度均较低。作者认为FDG-PET/CT可可靠排除残留/复发淋巴结病变,但HPV阳性肿瘤可靠性可能较低,最佳监测策略尚待确定。

要点

  • 治疗后6个月内FDG-PET/CT汇总敏感度85%、特异度93%,可可靠排除残留/复发淋巴结病变。
  • HPV阳性肿瘤敏感度75%低于HPV阴性89%,特异度87%低于95%。
  • 研究间存在显著异质性(p < 0.001)。

核心结论

  • 头颈部鳞状细胞癌患者(化疗)放疗后6个月内行FDG-PET/CT是排除残留/复发淋巴结病变的可靠方法,可避免治疗性干预。
  • FDG-PET/CT在HPV阳性肿瘤中可能可靠性较低,最佳监测策略尚待确定。

研究设计与样本

  • 系统综述,检索MEDLINE和Web of Knowledge数据库。
  • 从22项已识别研究中纳入20项研究进行Meta分析,共1293例患者。
  • 采用双变量随机效应模型汇总敏感度和特异度。

主要发现

  • 汇总敏感度为85%(95%CI 76-91%),特异度为93%(95%CI 89-96%),诊断比值比为76(95%CI 35-165)。
  • 以患病率10%设定,阳性预测值为58%,阴性预测值为98%。
  • 试验间存在显著异质性(p < 0.001)。
  • HPV阳性肿瘤敏感度为75% vs HPV阴性89%(p = 0.01),特异度为87% vs 95%(p < 0.005)。

关键数值与推荐

  • 汇总敏感度85%(95%CI 76-91%)、特异度93%(95%CI 89-96%)、诊断比值比76(95%CI 35-165)。
  • 患病率10%时,阳性预测值58%、阴性预测值98%。
  • HPV阳性肿瘤敏感度75% vs HPV阴性89%(p = 0.01),特异度87% vs 95%(p < 0.005)。

临床怎么用

  • 作者认为,头颈部鳞状细胞癌患者(化疗)放疗后6个月内行FDG-PET/CT可可靠排除残留/复发淋巴结病变并避免治疗性干预。
  • 作者指出,FDG-PET/CT在HPV阳性肿瘤中可能可靠性较低,最佳监测策略尚待确定。

局限性

  • 试验间存在显著异质性(p < 0.001)。
  • FDG-PET/CT在HPV阳性肿瘤中可能可靠性较低。
  • 最佳监测策略尚待确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18-fluorodeoxyglucose positron emission tomography combined with computed tomography (FDG-PET/CT) is increasingly used to evaluate treatment response in head and neck squamous cell carcinoma (HNSCC). This analysis assessed the diagnostic value of FDG-PET/CT in detecting nodal disease within 6 months after treatment, considering patient and disease characteristics. METHODS: A systematic review was performed using the MEDLINE and Web of Knowledge databases. The results were pooled using a bivariate random effects model of the sensitivity and specificity. RESULTS: Out of 22 identified studies, a meta-analysis of 20 studies (1293 patients) was performed. The pooled estimates of sensitivity, specificity and diagnostic odds ratio (with 95% CI) were 85% (76-91%), 93% (89-96%) and 76 (35-165), respectively. With the prevalence set at 10%, the positive and negative predictive values were 58% and 98%. There was significant heterogeneity between the trials (p < 0.001). HPV positive tumors were associated with lower sensitivity (75% vs 89%; p = 0.01) and specificity (87% vs 95%; p < 0.005). CONCLUSION: FDG-PET/CT within 6 months after (chemo)radiotherapy in HNSCC patients is a reliable method for ruling out residual/recurrent nodal disease and obviates the need for therapeutic intervention. However, FDG-PET/CT may be less reliable in HPV positive tumors and the optimal surveillance strategy remains to be determined.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Helsen N, Van den Wyngaert T, Carp L, et al. FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance. Eur J Nucl Med Mol Imaging. 2018. PMID: 29478080. doi:10.1007/s00259-018-3978-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。